Moreover, blocking CD36 in patient-derived prostate cancer xenograft (PDX) models reduces tumor growth in CD36high PDX models, suggesting a potential therapeutic benefit of blocking fatty acid uptake in CD36high prostate cancer [64]. This evidence concerns the gene CD36 and prostate cancer.